Emcure Pharmaceuticals is an award-winning pharmaceutical company, boasting an expansive product portfolio and presence across key therapeutic domains. Emcure’s IPO will likely present investors with attractive valuations.
Investors can easily check their allotment status of Emcure Pharmaceuticals IPO by visiting Link Intime India Pvt Ltd’s Registrar Website, which will update allotment within 20 minutes after closing bidding.
Date
Emcure Pharmaceuticals’ initial public offering (IPO) will launch for subscription on July 3 and close July 5 with price range of ₹960 to ₹1008 per share and lot size of 14. The company aims to raise up to Rs 6,722 crore through this sale, consisting of both fresh issue shares and offer for sale (OFS) shares, with fresh issue funds contributing directly to company coffers while OFS shares are not dilutive or equity dilutive.
Review
Emcure Pharmaceuticals manufactures and globally markets an expansive portfolio of pharmaceutical and biopharmaceutical products across major therapeutic areas. Operating 13 manufacturing facilities in India, they produce medications including pills, liquids, injectables and complex ingredients like chiral molecules and iron molecules – as well as being equipped with R&D capabilities that allow them to take advantage of emerging opportunities in key therapeutic areas.
The company’s operations are supported by an expansive distribution network comprised of over 5,000 stockists and 37 carry-and-forward agents, giving it extensive reach in domestic market. Furthermore, over 5,000 field personnel interact regularly with healthcare providers ensuring the business always keeps an ear to the ground.
Emcure Pharmaceuticals IPO comprises both fresh shares worth Rs800 crore, and an offer for sale (OFS) by existing promoters and shareholders worth Rs151 crore. With highly experienced management that should help expand business and achieve profitability, but global players as competitors for raw material suppliers could impede pricing or operations negatively; Emcure Pharmaceuticals represents a high degree of risk that should only be undertaken with guidance from your financial adviser.
Allotment
Emcure Pharmaceuticals IPO allotment details have been finalized, enabling investors who applied for this initial public offering (IPO) to view their status on Link Intime India Pvt Ltd registrar website and claim refunds through them if applicable.
Pune-based pharmaceutical manufacturer Lupin Limited develops, produces and global markets a broad selection of pharmaceutical products across various major therapeutic areas. Their differentiated portfolio comprises orals, injectables and biotherapeutics with presence in over 70 countries with special attention paid to India, Europe and Canada.
Over the last three years, this company has reported revenue growth and profitability; however, their cash and cash equivalents were negative in two financial years due to borrowings.
Emcure Pharma will use proceeds from its initial public offering (IPO) to pay back some outstanding debts and for general corporate purposes, and is estimated to receive total proceeds of around Rs 293 crore from this issue. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited and J P Morgan India Private Limited have been appointed book-running lead managers; Emcure Pharma is supported by Bain Capital. The issue will open for subscription on July 3 and close on July 5. Both BSE and NSE listings will allow investors access to Emcure Pharma stock shares during this IPO issue.
To know more about such news and also to find our more about Stock market , Forex market and cryptocurrency kindly follow us.
